What are the potential interactions between Daflon (micronized purified flavonoid fraction) and gabapentin?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 6, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

No Clinically Significant Interaction Between Daflon and Gabapentin

There is no documented or anticipated clinically significant interaction between Daflon (micronized purified flavonoid fraction) and gabapentin, and these medications can be safely used together.

Pharmacological Basis for Safety

Gabapentin's Minimal Interaction Profile

  • Gabapentin is not metabolized by the cytochrome P450 system and is primarily excreted unchanged through the kidneys, which minimizes the risk of metabolic drug interactions 1
  • Gabapentin has minimal drug interaction potential compared to other anticonvulsants 1
  • Studies demonstrate that gabapentin does not significantly interact even with renally excreted drugs like lithium, showing no alterations in pharmacokinetic parameters 2

Daflon's Pharmacological Properties

  • Daflon (containing diosmin and hesperidin) is a flavonoid preparation with minimal systemic absorption and negligible effects on drug-metabolizing enzymes
  • Research on flavonoids (quercetin and fisetin) combined with gabapentin actually shows potential synergistic benefits in neuropathic pain management without adverse interactions 3
  • Flavonoids do not significantly affect P-glycoprotein or CYP450 systems at therapeutic doses

Clinical Considerations

Monitoring Requirements

  • No specific monitoring is required for the combination of Daflon and gabapentin beyond standard clinical assessment for each individual medication 1
  • Monitor for gabapentin's typical side effects (sedation, dizziness, cognitive effects) as you would with any gabapentin therapy 1
  • Assess renal function if gabapentin is used, particularly in elderly patients or those with pre-existing renal impairment, but this is unrelated to Daflon co-administration 1

Special Populations

  • In elderly patients, start with lower doses of gabapentin (100-300 mg daily initially with gradual titration) due to age-related renal function decline, not due to interaction concerns 1
  • Gabapentin requires dose adjustment in patients with reduced renal function, but Daflon does not influence this requirement 1

Common Pitfalls to Avoid

  • Do not confuse Daflon with other medications: The evidence provided discusses interactions with anticoagulants (NOACs), antiepileptics that induce CYP450 enzymes, and other CNS-active drugs—none of which apply to Daflon 4
  • Do not assume all flavonoids interact: While some medications require caution with multiple agents, flavonoid preparations like Daflon lack the pharmacokinetic properties that would create interactions with gabapentin 3
  • Avoid unnecessary polypharmacy concerns: While polypharmacy increases interaction risk in general 5, the specific combination of Daflon and gabapentin does not represent a problematic pairing

References

Guideline

Gabapentin and Diclofenac Interaction Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Gabapentin does not alter single-dose lithium pharmacokinetics.

Journal of clinical psychopharmacology, 1998

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Potential drug-drug interactions in ICU patients: a retrospective study.

Drug metabolism and personalized therapy, 2020

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.